Two-Drug Strategy Reprograms Resistant Prostate Cancer Cells

Imagine a tumor that changes its face to avoid a bullet. That is exactly what some prostate cancers do: they shed glandular traits, slip out of the androgen-driven identity that therapies target, and reemerge stubbornly resistant. A team at the University of Michigan now reports a strategy that forces at least part of that masquerade to stop.

Prostate cancer is often slow, but not always. When it escapes the prostate and spreads, standard treatment relies on blocking androgen signaling. Those drugs can work well at first. Yet nearly every patient who develops metastatic disease eventually confronts resistance. The cancer doesn’t just survive; in many cases it morphs—losing gland-like features and activating programs more like stem cells. Scientists call that switch transdifferentiation. It’s a biological escape hatch.

Researchers digging into why this happens homed in on two genetic losses frequently seen in these shape-shifting tumors: TP53 and RB1. Losing those tumor suppressors nudges cancer cells toward a different identity. But which molecular levers actually drive the change? The Michigan group set out to find them by comparing cancer cell lines with and without those losses, tracking the pathways that flip when identity shifts occur.

Two pathways stood out. One arm of the problem involves chromatin readers—proteins that help turn on the gene programs of the new identity. Drugs called BET bromodomain inhibitors can blunt those readers and slow the activation of alternate cell programs. The other arm is an epigenetic silencing problem: glandular genes are often shut down by DNA methylation. That’s where DNA methyltransferase (DNMT) inhibitors come in; they can reactivate genes that had been silenced.

Image of typical glandular prostate adenocarcinoma, left, and prostate cancer with transdifferentiation.

Alone, each approach did something useful but incomplete. BET inhibitors slowed growth but rarely killed the stubborn cells. DNMT inhibitors can revive genes tied to glandular identity, and they’re already in clinical use for certain blood cancers. When the team combined the two—BET plus DNMT inhibitors—the result was more than additive. Cell cultures showed stronger growth suppression. Mouse models with implanted tumors mirrored that effect: tumor growth fell noticeably, even when the drugs were given at doses below typical clinical recommendations.

“We reversed a significant portion of the gene-expression changes that accompany the transition,” a laboratory member explained, noting that the dual treatment nudged cells back toward their original identity while tamping down the stem-like programs that fuel resistance. That reversal appears tied to reawakening glandular genes and simultaneously blocking the cell-fate machinery that drives transdifferentiation.

The practical upside is twofold. First, the combination achieved meaningful tumor control in models without obvious toxicity at lower doses—an encouraging safety signal. Second, because DNMT inhibitors are already FDA-approved for other diseases, the path to clinical testing could be faster than for an entirely new compound.

Still, questions remain. Which specific genes account for the anti-tumor effect? Can clinicians identify biomarkers that predict which patients will benefit? Can transdifferentiation be stopped before it starts—preventing the identity shift rather than trying to reverse it afterward? The researchers emphasize that knowing which tumors are poised to change could be the difference between reactive and preemptive therapy.

Beyond prostate cancer, there is wider relevance. Other malignancies—some lung and pancreatic cancers among them—also undergo identity switches that help them resist treatment. If the two-pathway approach proves robust, it might broaden into a strategy against diverse cancers that dodge therapy by changing who they are, biologically speaking.

Clinical trials will be the real test. For now, the study offers a clear concept: target the silencing and the switch together, and you may corner a tumor that otherwise slips through single-agent nets. It’s a reminder that the toughest cancers don’t merely grow faster; they change the game, and sometimes the best response is to change the playbook.